• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Amarin

edit

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin’s cardiovascular programs capitalize on Amarin’s expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. Amarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN)

Recent Milestones

edit

• 
  Amarin — has named Paul Huff, an industry veteran with cholesterol drug commercialization under his belt, as chief commercial officer (2/2/11)
  Posted 2/3/11 at 3:54am via masshightech.com
• 
  Amarin — has announced a planned $100.2 million financing stemming from a public offering of American Depositary Shares (1/7/11)
  Posted 1/10/11 at 6:50am via masshightech.com
• 
  Amarin — has announced a planned $100.2 million financing stemming from a public offering of American Depositary Shares (1/7/11)
  Posted 1/10/11 at 6:50am via masshightech.com
• 
  Amarin — reporting positive, statistically significant top-line results from its first Phase 3 clinical trial of lead drug candidate AMR101 (11/29/10)
  Posted 11/30/10 at 6:16am via masshightech.com
• 
  Amarin added Dr. Declan Doogan as Chief Medical Officer . (10/1/09)
  Posted 5/10/13 at 2:07am
• 
  Amarin added John Thero as CFO.
  Posted 8/18/10 at 6:14pm
• 
  Amarin added Colin Stewart as President and CEO.
  Posted 8/18/10 at 6:14pm

Videos

Screenshots

edit

Sources

Amarin treatment for high triglycerides shows progress in trials (masshightech.com) [edit]
Amarin expecting $100M financing (masshightech.com) [edit]
Amarin expecting $100M financing (masshightech.com) [edit]
Amarin names Huff to lead cholesterol drug commercialization (masshightech.com) [edit]